Author

Noriyo Nagata

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Eosinophil-driven immunopathology exacerbates SARS-CoV-2 pneumonia in an OVA-induced airway allergy mouse model

ABSTRACT Asthma is an allergic airway disease characterized by distinct immune environments that can alter host responses to respiratory viral infections; however, its impact on coronavirus disease 2019 (COVID-19) severity remains unclear. To investigate how allergic airway inflammation affects severe acute respiratory...

Takao Iketani, N. Iwata-Yoshikawa, Yusuke Sakai et al. · Msphere · 0 citations

Open access Oct 2026

Persistent SARS-CoV-2 infection in SCID rats reflects immune vulnerability of the upper airway and trachea

ABSTRACT In immunocompromised patients, persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries the risk of prolonged viral shedding and emergence of new variants. To reproduce the key features of persistent SARS-CoV-2 infection and evaluate its transmissibility, mouse-passaged SARS-Co...

Kaya Miyazaki, Nozomi Shiwa-Sudo, N. Iwata-Yoshikawa et al. · Microbiology spectrum · 0 citations

Aug 2026

A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.

Overall, NIID-002 fulfills the key requirements for the pandemic preparedness of CVV, combining reduced pathogenicity, broad antigenic reactivity, and adequate production efficiency, which underscores the continued need for surveillance and refinement of influenza vaccine strategies to address evolving viral threats.

Yasushi Suzuki, Tomoko Arita, Masayuki Shirakura et al. · Vaccine · 0 citations